ViaNautis
@ViaNautisBio
Followers
45
Following
5
Media
5
Statuses
16
ViaNautis Bio Targeted Nanomedicines
Cambridge, UK
Joined September 2021
We’re excited to announce our collaboration with @EliLillyandCo to advance genetic medicines using ViaNautis’ #polyNaut® platform. Together, we’re working to deliver targeted therapies to address unmet medical needs: #ViaNautis #Biotech #Nanomedicine
0
1
0
We’re delighted to welcome Dr Ray Jupp as ViaNautis Bio's new CSO! Joining soon after the appointment of Adi Hoess as CEO, Ray will oversee scientific strategy and R&D activities. #ViaNautis
0
1
1
We are delighted to welcome Dr Adi Hoess as the new CEO of ViaNautis Bio! Read more about his appointment: #ViaNautis #polyNaut #leadership #Biotech
0
1
2
We are delighted to announce the appointment of.Dr Steven M. Altschuler as the new Chairman of ViaNautis. Dr Altschuler will support ViaNautis as we seek to unlock the delivery of genetic treatments across hard-to-penetrate biological barriers.
vianautis.com
ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Steven M. Altschuler as independent...
0
0
0
Thanks to our investors and stakeholders for their unwavering support. For the full press release click here: [.#ViaNautis #polyNaut.
vianautis.com
– ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases...
0
0
0
The funds will drive product development using our polyNaut® platform, , expand our teams, and establish state-of-the-art lab facilities. PolyNaut technology enables precise intracellular delivery. #polyNaut #Nanotechnology.
1
0
1
We are delighted to announce an oversubscribed Series A fundraise of $25m. Formerly SomaServe, ViaNautis has gained support from both new and existing investors to drive the next generation of genetic nanomedicines.#ViaNautis #Biotech.
1
4
7
RT @cofinitive: #21toWatch Top21.2023 winner @SomaServeLtd is delivering the next generation of genetic medicines. Their PolyNaut polymer n….
0
1
0
RT @cofinitive: .@SomaServeLtd are delivering the next generation of genetic medicines. Its PolyNaut polymer nanoparticle platform enables….
0
1
0
RT @NewNanomedic: Great to be part of the @SomaServeLtd team who received an award for the PolyNaut®️ technology #21towatch Read more here….
0
1
0
Today our VP of Business Development Sam Barker joins the Careers in Discovery podcast to discuss his early career in drug discovery and moving into business development, building collaborations and partnerships for our polyNaut platform.
Join us on the Careers in Discovery podcast as we speak to @DrSPBarks, VP of Business Development at @SomaServeLtd about BD in start up Biotech, transitioning from research into commercial and more. To listen to the interview, head to Enjoy!. #podcast
0
0
2
Congratulations Virginia!.
Parabens (congratulations) to Virginia from @SomaServeLtd for getting a good chunk of her PhD work published. She proved that phosphoryl choline #polymersomes are #antiinflammatory among other things . @MolBionics
0
0
0
Thank you @cofinitive!. Our PolyNaut platform addresses the ‘delivery problem’ of how target advanced therapies to the site of action. We use PolyNaut to pioneer new medicines for crossing the BBB and other biological barriers.
We've just updated the #21toWatch People, Companies and 'Things' lists! Congrats to Anna Sturrock (@otolithgirl), Alex Justin, Superdielectrics, @QkineBio, @CamAPS_FX and PolyNaut® Technology by @SomaServeLtd
1
1
2
Next week CEO Francesca Crawford and VP Bus Dev Sam Barker will be attending #BIOEurope. To hear more about how we are using our PolyNaut technology to develop a next generation of gene therapies and intracellular proteins in oncology, immunology and CNS disorders, get in touch!
1
0
1
Reaching the site of action is one of the biggest challenges facing gene therapy and protein therapeutics for intracellular targets. SomaServe works in partnership to pioneer new therapies for crossing the Blood Brain Barrier (BBB) using targeted polymer nanoparticles
0
0
1
We're looking forward to attending #BIOEurope next week and participating in the UK virtual pavillion!. Get in touch if you would like to learn more about how we are using our PolyNaut technology to develop a next generation of gene therapies and intracellular proteins.
0
0
2